Dyne Therapeutics to Showcase Innovations at Key Conferences

Author: Evelyn Baker Updated: 08-27-2025 07:46 AM

Exciting Updates from Dyne Therapeutics

Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage company focused on enhancing the lives of individuals with genetically driven neuromuscular diseases, has announced its participation in two major investor conferences. These events represent an opportunity for Dyne to share its latest advancements and research in the field, highlighting its commitment to delivering innovative treatments.

Upcoming Conferences

The first event is the Cantor Global Healthcare Conference 2025, scheduled for Friday, September 5, at 9:45 a.m. ET. This fireside chat will take place in New York and promises to be an engaging forum for discussing Dyne's initiatives.

Shortly after, on Monday, September 8, at 9:15 a.m. ET, Dyne Therapeutics will present at the Morgan Stanley 23rd Annual Global Healthcare Conference, also in New York. This conference will highlight the company’s progress and future plans in neuromuscular disease therapies.

Webcast Availability

For those who are unable to attend, Dyne will provide a live webcast of each presentation. Interested individuals can find the webcasts in the Investors & Media section of Dyne's website. Recordings of the presentations will be available for 90 days, ensuring that all stakeholders can stay informed on the latest developments.

About Dyne Therapeutics

Dyne Therapeutics is dedicated to creating therapeutic solutions that address the underlying causes of genetically driven neuromuscular diseases. The company is currently advancing clinical programs that target myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), alongside preclinical efforts focused on facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

At Dyne, the mission is clear: to provide functional improvement for patients and their communities. This commitment drives the development of innovative therapies aimed at improving the quality of life for individuals dealing with these challenging conditions.

Research and Development Focus

The ongoing research at Dyne Therapeutics is centered on innovative technologies designed to enhance muscle function and central nervous system responses. By focusing on these areas, Dyne is paving the way for groundbreaking treatments that could transform care for patients with neuromuscular diseases.

Get in Touch

For investors and stakeholders who wish to learn more or have inquiries, they can reach out to Mia Tobias at Dyne Therapeutics by emailing ir@dyne-tx.com or by calling 781-317-0353. For media inquiries, Stacy Nartker can be contacted at snartker@dyne-tx.com and is available at 781-317-1938.

Frequently Asked Questions

What is Dyne Therapeutics known for?

Dyne Therapeutics specializes in developing therapies for genetically driven neuromuscular diseases, focusing on improving the quality of life for affected individuals.

When will Dyne be presenting at investor conferences?

Dyne Therapeutics will present at the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley Global Healthcare Conference on September 8.

How can I listen to Dyne's presentations?

Live webcasts of the presentations can be found in the Investors & Media section on Dyne's website, with replays available for 90 days.

What therapeutic areas is Dyne targeting?

Dyne is targeting myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease.

Who can I contact for more information about Dyne Therapeutics?

For investor relations, contact Mia Tobias at ir@dyne-tx.com, and for media inquiries, reach out to Stacy Nartker at snartker@dyne-tx.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.